ASCO GU 2023: Estimated cost of adverse event management for patients with metastatic renal cell carcinoma treated with VEGFR TKI

Click Here To View Our ASCO Poster:

TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)